Pfizer-BioNTech Vaccine Is Efficient Against UK COVID Variant, PFE Stock Slightly Up
The vaccine from the duo of Pfizer-BioNTech as well as Moderna is expected to fetch the firms as much as $15 billion in sales by the year 2023.
Pfizer Covid-19 Vaccine Is on Track to Be Submitted for Regulatory Review in October
Pfizer COVID-19 vaccine created in cooperation with BioNTech SE is to be submitted for review in October. The duo will not accept any payments until they have successfully manufactured an effective vaccine.
PFE Up 4%, BNTX Up 10%, U.S. Government to Pay $1.95B to Pfizer, BioNTech for COVID-19 Vaccine
By
Tolu Ajiboye
The U.S. Government has signed a $1.95 billion deal with Pfizer and BioNTech for their COVID-19 vaccine. The prices PFE and BNTX stocks are moving higher.
Pfizer (PFE), BioNTech (BNTX) Stocks Surge, Their Coronavirus Vaccine Candidates Get ‘Fast Track’ Designation
By
Tolu Ajiboye
Pfizer and BioNTech stocks have jumped in response to receiving ‘Fast Track’ status on their coronavirus vaccine candidates. PFE and BNTX prices are rising.
Pfizer (PFE) Shares Gained 1.72% After Hours as Company’s Coronavirus Drug Looks Promising
Pfizer had initially planned to enter clinical trials for its coronavirus drug by the end of the year. Now it hopes to start the trials in the third quarter. Pfizer shares price is rising.